Evidence map›Paper›PMID 29512598›Full record

ReviewThe Indian journal of medical research2017

Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.

Onur Esbah, Berna Oksuzoglu

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Indian journal of medical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. The functional TNF-αBreast cancer research and treatment · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Onur EsbahDepartment of Medical Oncology, School of Medicine, Duzce University, Duzce, Turkey.
Berna OksuzogluDepartment of Medical Oncology, School of Medicine, Erzincan University, Duzce, Turkey.
Düzce Üniversitesi · TRErzincan Binali Yıldırım University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a heterogeneous disease and may present with different clinical and biological characteristics. At present, breast cancer is divided into molecular subgroups besides its histopathological classification. Decision for adjuvant chemotherapy is made based on not only histopathological characteristics but also molecular and genomic characteristics using indices, guidelines and calculators in early-stage breast cancer. Making a treatment plan through all these prognostic and predictive methods according to risk categories aims at preventing unnecessary or useless treatments. In this review, an attempt to make a general assessment of prognostic and predictive methods is made which may be used for planning individualized therapy and also the comments of the guidelines used by the oncologists worldwide on these methods.

Indexed as

Chemotherapy, AdjuvantPrognosisBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansKi-67 AntigenNeoplasm StagingPrecision MedicineERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesESR1 protein, humanEstrogen Receptor alphaKi-67 AntigenAdjuvant chemotherapy - early-stage breast cancer - predictive - prognostic

Identifiers

PMID29512598
PMCPMC5861467
OpenAlexW2802036957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.